by qfrsolutions | Aug 25, 2016 | News
Source: FierceBiotech The late-stage skin condition biotech Novan is looking to batter ongoing headwinds and gun for a $60 million public offering. The Durham, NC-based company, which is around a decade old, is working on nitric oxide based therapies for dermatologic...
by qfrsolutions | Aug 15, 2016 | News
Source: Allergan ($AGN) thinks facial injectable Kybella has the potential to one day bank Botox-level sales. And the company is starting up a couple new studies to help it get there. The Dublin drugmaker is initiating trials of the med in bra-line fat and fat around...
by qfrsolutions | Aug 11, 2016 | News
Source: Reuters U.S. prosecutors have opened a criminal investigation into Valeant Pharmaceuticals International Inc (VRX.N) over whether it hid from insurers its relationship with a specialty pharmacy that helped boost its drug sales, the Wall Street Journal reported...
by qfrsolutions | Aug 1, 2016 | News
Source: Real Money Valeant Pharmaceuticals’ (VRX) new CEO Joseph Papa may have spoken too soon in his pledge to begin to curb drug prices that had been hiked to controversial levels — especially as the drugmaker’s roughly $31 billion debt package did...
by qfrsolutions | Jul 25, 2016 | News
Source: CNBC Journey Medical Corporation, a subsidiary of Fortress Biotech, Inc. (FBIO), launched the first two prescription products in its dermatology franchise, Luxamend™ Wound Cream and Ceracade™ Skin Barrier Emulsion. Both products will be showcased...
by qfrsolutions | Jul 13, 2016 | News
Source: The Wall Street Journal Michael Pearson has sold nearly $100 million of his stock in Valeant Pharmaceuticals International Inc. in the past two weeks, according to securities filings, following his firing as the troubled drugmaker’s chief executive in...
